BioArctic AB

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0010323311
SEK
317.20
-2 (-0.63%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

71.72 k

Shareholding (Dec 2025)

FII

0.00%

Held by 2 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

High Management Efficiency with a high ROE of 15.35%

 
2

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of -8.97

 
3

Healthy long term growth as Net Sales has grown by an annual rate of 100.08% and Operating profit at 78.36%

 
4

Negative results in Dec 25

5

With ROE of 52.40%, it has a fair valuation with a 13.23 Price to Book Value

6

Majority shareholders : Non Institution

 
7

Market Beating Performance

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 26,805 Million (Mid Cap)

stock-summary
P/E

25.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.11

stock-summary
Return on Equity

51.97%

stock-summary
Price to Book

13.63

Revenue and Profits:
Net Sales:
184 Million
(Quarterly Results - Dec 2025)
Net Profit:
-9 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-0.94%
0%
-0.94%
6 Months
11.06%
0%
11.06%
1 Year
76.91%
0%
76.91%
2 Years
44.71%
0%
44.71%
3 Years
30.21%
0%
30.21%
4 Years
212.82%
0%
212.82%
5 Years
251.86%
0%
251.86%

BioArctic AB for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
100.08%
EBIT Growth (5y)
78.36%
EBIT to Interest (avg)
-8.97
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.28
Sales to Capital Employed (avg)
0.58
Tax Ratio
3.43%
Dividend Payout Ratio
17.32%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
17.86%
ROE (avg)
15.35%

Valuation key factors

Factor
Value
P/E Ratio
25
Industry P/E
Price to Book Value
13.23
EV to EBIT
19.58
EV to EBITDA
19.58
EV to Capital Employed
186.26
EV to Sales
13.46
PEG Ratio
0.02
Dividend Yield
NA
ROCE (Latest)
951.43%
ROE (Latest)
52.40%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 2 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 38.03% vs -66.00% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 89.87% vs -189.96% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "184.00",
          "val2": "133.30",
          "chgp": "38.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "37.80",
          "val2": "-21.40",
          "chgp": "276.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.90",
          "val2": "2.70",
          "chgp": "81.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.80",
          "val2": "-86.90",
          "chgp": "89.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "188.40%",
          "val2": "-185.50%",
          "chgp": "37.39%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 676.65% vs -58.21% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 677.24% vs -177.27% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,999.10",
          "val2": "257.40",
          "chgp": "676.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,381.00",
          "val2": "-205.20",
          "chgp": "773.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "37.90",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,022.30",
          "val2": "-177.10",
          "chgp": "677.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "684.40%",
          "val2": "-892.20%",
          "chgp": "157.66%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
184.00
133.30
38.03%
Operating Profit (PBDIT) excl Other Income
37.80
-21.40
276.64%
Interest
4.90
2.70
81.48%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-8.80
-86.90
89.87%
Operating Profit Margin (Excl OI)
188.40%
-185.50%
37.39%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is 38.03% vs -66.00% in Sep 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 89.87% vs -189.96% in Sep 2025

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
1,999.10
257.40
676.65%
Operating Profit (PBDIT) excl Other Income
1,381.00
-205.20
773.00%
Interest
37.90
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
1,022.30
-177.10
677.24%
Operating Profit Margin (Excl OI)
684.40%
-892.20%
157.66%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 676.65% vs -58.21% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 677.24% vs -177.27% in Dec 2024

stock-summaryCompany CV
About BioArctic AB stock-summary
stock-summary
BioArctic AB
Pharmaceuticals & Biotechnology
BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.
Company Coordinates stock-summary
Company Details
Warfvinges vag 35 , STOCKHOLM None : 112 51
stock-summary
Tel: 46 8 695693046 869 56930
stock-summary
Registrar Details